Topic Archives: coronavirus

Today I’m getting a lot of questions about the “Coronavirus Recovery Package” being pitched by Alexander Green — he’s selling Oxford Club subscriptions ($99) by promising a special report called “The Three Biggest Winners of the Coronavirus Recovery.” Green’s big-picture intro is pretty reasonable and rational, and similar to lots of other folks these days […]

I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]

This is the latest teaser pitch that a lot of folks have been asking about — and rightly so, I expect, because it’s designed to be extremely topical and get you revved up immediately. Here’s the intro to the ad that I’ve seen in some Angel Publishing newsletters: “We’re now in crisis mode over coronavirus […]

It’s been a roller coaster ride so far this week. I’m a beginner in investing and waiting for the market selloff to reach the bottom. Given the situation that coronavirus just started spreading in US, anyone who can read the situation comment on what could be possible bottom or did we already reach it with […]

Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), I’m going to make those coronavirus updates brief – it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic – and, yes, it now certainly looks like […]

Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw.   My impressions and conclusions are in some cases only loosely based on […]

Comments

  • Avatar

    Yes, there is the small possibility that a vaccine could make your reaction to the pathogen worse. That's one of the th...

  • Avatar

    I'm surprised you didn't bring up leronlimab. Mark this note....it will be the leading therapy for COVID-19 in short or...

  • Avatar

    Regarding C19 treatments, one you should keep your eye on is Leronlimab from Cytodyn, a small cap pharma. A BLA for HIV...

  • Avatar

    Agreed... My money is on CYDY for HIV and cancer, but C19 trials are eye opening.... This coming week will tell the tail...

  • Avatar

    In 1979 I began college for a pharmacy degree. My father in law was an emeritus professor at University of Michigan sch...

  • Avatar

    CEO of Co-Diagnostics $CODX was on Varney (FBN) on 3/5 mentioning the fact that recent relaxation of FDA restrictions no...

  • Avatar

    Headline from 3/1: Vaxart, Inc. (NasdaqGS: VXRT), a clinical-stage biotechnology company developing oral recombinant vac...

  • Avatar

    TOMZ recent headline: https://finance.yahoo.com/news/steramist-declared-official-decontamination-technology-143010170.ht...

  • Avatar

    Just some ideas: "CODX", maker of diagnostic kits for Covid-19 could go vertical once approved by FDA/CDC. The stock ha...

  • Avatar

    Great and informative article from a medical prospective. What stocks do u all think will rally, even if temporarily, du...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch